240 related articles for article (PubMed ID: 37022356)
1. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J; Leventhal JS
Crit Rev Immunol; 2022; 42(4):1-20. PubMed ID: 37022356
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
4. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
5. Adverse cutaneous drug eruptions: current understanding.
Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
[TBL] [Abstract][Full Text] [Related]
6. The life-threatening eruptions of immune checkpoint inhibitor therapy.
Coleman EL; Olamiju B; Leventhal JS
Clin Dermatol; 2020; 38(1):94-104. PubMed ID: 32197753
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
8. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.
Orime M
J Immunol Res; 2017; 2017():6928363. PubMed ID: 29226159
[TBL] [Abstract][Full Text] [Related]
9. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
10. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
[TBL] [Abstract][Full Text] [Related]
12. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.
Kuo AM; Markova A
Front Med (Lausanne); 2022; 9():898790. PubMed ID: 35770005
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis of severe cutaneous drug eruptions.
Bachot N; Roujeau JC
Am J Clin Dermatol; 2003; 4(8):561-72. PubMed ID: 12862499
[TBL] [Abstract][Full Text] [Related]
14. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
15. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
17. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
[TBL] [Abstract][Full Text] [Related]
20. [Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1790-1803. PubMed ID: 38782747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]